Inhibikase Therapeutics Inc
NASDAQ:IKT

Watchlist Manager
Inhibikase Therapeutics Inc Logo
Inhibikase Therapeutics Inc
NASDAQ:IKT
Watchlist
Price: 1.76 USD -6.88% Market Closed
Market Cap: 130.8m USD

EV/EBIT
Enterprise Value to EBIT

-1
Current
0.1
Median
5.9
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-1
=
Enterprise Value
43.5m USD
/
EBIT
-44.2m USD
EBIT Growth EV/EBIT to Growth
US
Inhibikase Therapeutics Inc
NASDAQ:IKT
Average EV/EBIT: 18.3
Negative Multiple: -1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 427.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.5
28%
0.8
US
U
US BioTec Inc
OTC:USBC
Not Available N/A N/A
US
Amgen Inc
NASDAQ:AMGN
18.4
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.4
12%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -562 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.1
17%
1.2
AU
CSL Ltd
ASX:CSL
18.6
16%
1.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.9
10%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -313 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-1.1
2-Years Forward
EV/EBIT
-0.9
3-Years Forward
EV/EBIT
-0.7